Angiogenesis is necessary for tumor growth, metastasis, and survival. Vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) and their receptors are key regulators of tumor vasculature. Based on preclinical studies demonstrating tumor suppression and survival advantage in mouse models when targeting both of these pathways combined with low dose cyclophosphamide, we performed a dose finding and pharmacokinetic study of sorafenib, low-dose oral cyclophosphamide and bevacizumab in children and young adults with refractory/recurrent solid tumors. Our results show that this drug combination is tolerable, has promising anti-tumor activity in a variety of tumors, and would be well-suited for maintenance therapy in the setting of minimal residual disease. PK and PD studies were performed during the first course.
TRANSLATIONAL RELEVANCE
Angiogenesis is necessary for tumor growth, metastasis, and survival. Vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) and their receptors are key regulators of tumor vasculature. Based on preclinical studies demonstrating tumor suppression and survival advantage in mouse models when targeting both of these pathways combined with low dose cyclophosphamide, we performed a dose finding and pharmacokinetic study of sorafenib, low-dose oral cyclophosphamide and bevacizumab in children and young adults with refractory/recurrent solid tumors. Our results show that this drug combination is tolerable, has promising anti-tumor activity in a variety of tumors, and would be well-suited for maintenance therapy in the setting of minimal residual disease. 4 The recommended phase II doses are sorafenib, 90 mg/m 
INTRODUCTION
Angiogenesis is necessary for tumor growth, metastasis, and survival. Vascular endothelial growth factor (VEGF) and its receptors, VEGFR-1 and VEGFR-2, and platelet derived growth factor (PDGF) and its receptors are key regulators of tumor vasculature. In preclinical models, dual inhibition of VEGF and PDGF signaling with low-dose, continuous "metronomic" chemotherapy results in more effective tumor suppression and improved survival. (1, 2) Additionally, more robust inhibition of VEGF signaling may be achieved by redundant inhibition of VEGF receptors and its ligand. This strategy may not only hinder angiogenesis and tumor growth but also circumvent resistance by impeding the feedback loop from elevated VEGF levels resulting from VEGF receptor inhibition. (3) (4) (5) Bevacizumab (Avastin; Genentech, San Francisco, CA) is a VEGF-specific recombinant, humanized monoclonal antibody that binds directly to all four VEGF isoforms with high affinity and is approved for use in adults. In a pediatric phase I study of single-agent bevacizumab in patients with refractory solid tumors, no dose-limiting toxicities (DLTs) were observed when three dose levels (5, 10, and 15 mg/kg every 2 weeks) were studied. No objective responses were observed. Five patients had disease stabilization for more than 3 months. (6) Sorafenib tosylate (BAY 43-9006, Nexavar, Bayer Health Care Pharmaceuticals, Wayne, NJ) is an orally bioavailable multi-target kinase inhibitor of Raf-1, BRAF, FLT-3, p38α, and cKit as well as VEGFR-2, VEGFR-3, and PDGFRB. Sorafenib is approved for the treatment of adults with advanced renal cell carcinoma and unresectable hepatocellular carcinoma at 400 mg twice daily. In a pediatric phase I single agent study, the maximum tolerated dose (MTD) of sorafenib was 200 mg/m 6 hand-foot syndrome (HFS), rash, hypertension, and elevated ALT. No objective responses were observed.
Cyclophosphamide is a commonly chosen chemotherapy agent for continuous low-dose administration because of its good oral bioavailability, minimal toxicity at low doses, and extensive clinical use. Low-dose continuous oral dosing of cyclophosphamide has been used in adult and pediatric studies, usually in combination with other cytotoxic agents, with minimal toxicity. (8) (9) (10) (11) (12) (13) We conducted a single-institution phase I study of sorafenib, bevacizumab, and low-dose cyclophosphamide to define the toxicity profile, DLTs, and MTD of this combination in children and young adults with refractory or recurrent solid tumors. Pharmacokinetic studies of sorafenib and cyclophosphamide were performed along with pharmacodynamic studies, including serial sampling of angiogenic factors in the plasma and contrast-enhanced ultrasound to assess changes in tumor blood flow during therapy.
PATIENTS AND METHODS

Patient Population
Eligibility criteria included: solid tumor recurrent/refractory to standard therapy; age ≤ 21 years at initial diagnosis, life expectancy ≥ 8 weeks, Karnofsky/Lansky performance score of > 50 and body surface area > 0.3 m or a normal serum creatinine for age, urine protein less than 1+ or ≤ 500 mg protein/24 hour urine collection. Patients with solid tumors metastatic to bone marrow were eligible for study but not evaluable for hematologic toxicity. Cardiac shortening fraction > 28%, corrected QT interval < 440, and hypertension well controlled for at least 2 weeks were required for study entry. Patient must have fully recovered from the acute toxic effects of all prior therapy; received no myelosuppressive therapy within 2 weeks, no biologic therapy within 7 days, no focal irradiation within 2 weeks, no craniospinal, total body, or whole pelvis irradiation within 3 months, no medications known to inhibit platelet function or induce cytochrome P450 enzyme within 1 week, no hematopoietic growth factors within 1 week prior to study entry; no current or recent use of full-dose anticoagulants; no allogenic transplant within 3 months of study entry; negative pregnancy test if female; not breast-feeding if female; agreed to use an effective contraceptive method if male or female of reproductive potential. Exclusion criteria included: a history of deep venous or arterial thrombosis within 3 months of study entry, known bleeding diathesis or coagulopathy, known hypersensitivity to recombinant human antibodies, myocardial infarction, severe or unstable angina, or severe peripheral vascular disease or a chronic nonhealing wound, ulcer, or bone fracture, or a major surgical procedure or significant traumatic injury within 28 days of study entry, and uncontrolled infection or evidence of intratumoral central nervous system hemorrhage on brain imaging prior to study entry.
Written informed consent was obtained from patients, parents, or legal guardians, with assent as appropriate. The protocol was approved by the institutional review board, which later approved review of the St. Jude medical records of those who continued treatment after removal from protocol therapy. Sorafenib was administered as a combination of capsules (compounded from the commercially available 200 mg tablets in strengths of 10, 20, 50, and 100 mg). Capsules were opened and sprinkled on low to moderate fat-containing soft foods for administration to children who could not swallow capsules.
Drug Administration and Study Design
The study followed a traditional 3-plus-3 phase I design. The MTD was defined as one A course could be repeated if the patient had at least stable disease and had recovered from the prior course of therapy such that the hematologic entry criteria had been met, hypertension and proteinuria were adequately controlled, and other drug-related adverse events were ≤ grade 1 or baseline, whichever was highest. Patients with grade 3 nonhematologic toxicity, with the specific exception of hypertension, nausea/vomiting, or electrolyte imbalances adequately controlled with medications/supplementations, which did not resolve to ≤ grade 1 or baseline within 2 weeks after completion of a course, were not permitted to resume therapy. Patients could continue on study treatment for a maximum of 24 courses if there was no disease progression or unacceptable toxicity.
Pharmacokinetic Studies
Pharmacokinetic studies for sorafenib and cyclophosphamide were performed in consenting patients.
Peripheral blood (1.5 mL) was collected after the first dose on day 1 before and 0.5, 2.0, 4.5, 6.0, 7.5, 24, and 48 h after sorafenib administration. After the first dose, sorafenib was withheld until the morning of day 3 (after the 48 h blood sample was obtained). Blood samples were also obtained during course 1 before sorafenib treatment on days 7, 13, and 21. Samples were centrifuged for 10 min at 3000×g and plasma was stored at -20ºC until analysis. Sorafenib and the active metabolite sorafenib N-oxide were measured in human plasma using a validated analytical method based on high-performance liquid chromatography with tandem mass spectrometric detection, as previously described. Contrast-enhanced ultrasound (CEUS) of a single target lesion was performed at baseline, on days 3 and 7 (± 2 days), at the end of courses 1 and 2, and then every other course and off treatment in consenting patients who had tumor that was visible on non-contrast enhanced sonography and met our institutional CEUS screening criteria. Our institutional CEUS criteria require patients to have a normal twelve lead ECG and echocardiogram with no evidence of right-to-left or bidirectional intracardiac shunting or pulmonary hypertension, an oxygen saturation of at least 92% on room air and no history or allergy to perflutren. In eligible patients, a perflutren contrast agent consisting of an injectable suspension of human serum albumin microspheres encapsulating octafluoropropane gas (Optison, General Electric Heath Care, Princeton, NJ) was administered at a dose of 0.3 mL to children weighing < 20 kg and 0.5 mL to those ≥ 20 kg. The contrast injection was followed by a 5 mL flush of normal saline. Because the contrast agent microspheres approximate the size of a red blood cell (range, 2-4.5 µm) they remain in the intravascular space and serve as a surrogate marker for tumor blood flow. A region of interest (ROI) within each tumor was identified for analysis. Using contrast-specific software, each ROI was evaluated for change in signal intensity from pre-contrast baseline to initial postcontrast peak (∆SI, in decibels) and rate of signal intensity increase from baseline to initial peak (RSI, decibels per second). The examination was considered successful if a 5 dB increase in signal intensity was detected. When < 5 dB was detected, the dose was doubled and the examination repeated. If the second dose did not result in at least a 5 dB increase, the study was considered unsuccessful, and the patient did not undergo further CEUS during follow-up.
Imaging parameters at baseline and at follow-up were compared to determine whether a change occurred that might indicate altered tumor blood flow in response to protocol therapy. In consenting patients whose tumor evaluations were suitable for MRI imaging, dynamic contrast-enhanced MR imaging (DCE-MRI) was obtained at baseline, on day 7, at the end of courses 1 and 2, and then every other course. Dynamic MR studies consist of rapid sequential T1-weighted imaging before, during, and after delivery of a paramagnetic contrast agent into the tumor capillaries and its subsequent diffusion into the extravascular space. These sequential imaging sets were then analyzed using a pharmacokinetic model accounting for microvascular transport (K trans ), vascular volume (v p ), and extracellular/extravascular space (v e ). Because the CEUS agent remains in the intravascular space, we anticipated a correlation between the DCE-MRI measure of v p and the CEUS measure of ∆SI.
Plasma VEGF, soluble VEGFR2 (sVEGFR2), soluble VEGFR3 (sVEGFR3), and PDGF-AB were quantified at baseline and on days 3, 7, 14, and 21 of course 1 using commercially available validated ELISA kits (RayBiotech, Inc., Norcross, GA) that included positive and negative controls, and quantified proteins with which to generate a standard curve. At the same time points, blood samples were also obtained to measure circulating endothelial cells (CECs: CD45-, CD34+, CD31+, CD133-) and circulating endothelial progenitors (CEPs: CD45-, CD34+, CD31+, CD133+). CECs and CEPs were measured by six-color flow cytometry using FACS LSR II machine (Becton Dickson, San Jose, CA) as previously described. (18) The antibodies used were against CD31, CD45, CD133, and CD34.
Statistical Methods
The exact Wilcoxon sign test was used to test for differences in plasma protein levels and 
Spearman rank correlation. The response rate was estimated and reported with a 95% Blyth-StillCasella confidence interval. Duration of response was defined as the time the RECIST criteria were met for objective response to the date of disease progression.
RESULTS
Patient Characteristics
Nineteen eligible patients were enrolled, all of whom were evaluable for toxicity. Patient characteristics are listed in Table 1 . The median number of courses administered per patient was 4 (range, 1-23) and the total number of courses completed was 86.
Toxicity and MTD
No DLTs were observed in 3 patients at the first dose level (sorafenib 90 mg/m With the exception of HFS, other significant toxicities frequently described in adults receiving bevacizumab and/or sorafenib were uncommon. In most cases, bleeding was limited to self-limited epistaxis, and complaints of fatigue did not interfere with activities of daily living.
One patient had grade 2 hypertension which was well controlled with amlodipine and one had grade 2 left ventricular dysfunction requiring interruption of study medications for one week.
One patient had a thrombus at the tumor site 5 days after the initiation of therapy that was most Two patients developed cystitis, one during course 2 and the other during course 5.
Intravenous or oral fluids to facilitate hydration and medications for bladder spasms/pain were administered with symptomatic improvement. However, one patient elected to discontinue study therapy because of this complication.
Pharmacokinetics Studies
Sorafenib first-dose pharmacokinetic studies were performed in 15 patients (Table 3) . Table 4 and were similar at both dose levels. There was no correlation between the sorafenib steady-state plasma concentrations during the first course and the development of DLT.
Cyclophosphamide pharmacokinetic studies were performed in 18 patients. Of these 18 patients, 7 received the cyclophosphamide dose in tablet form versus 11 patients who received the dose as a liquid formulation. The median (range) cyclophosphamide absorption rate constant, apparent oral clearance, and apparent volume of distribution were 0.17 hours (1.9 to 7.6 µM*h), and 3.0 µM*h (1.9 to 5.5 µM*h), respectively. The AUC 0-∞ for the active metabolite, 4-hydroxy-cyclophosphamide, was on average ~5% higher when the cyclophosphamide oral formulation was administered as a liquid vs. tablet, but the difference was not found to be statistically significant (p = 0.82).
Pharmacodynamics Studies
Seven patients consented to CEUS. Two baseline CEUS examinations were excluded for technical difficulties; 1 was excluded because the femoral node evaluated was not biopsy-proven to represent metastatic disease. The remaining 4 (age range, 21 months to 15 years) underwent a total of 22 CEUS examinations of target lesions. Results are shown in Figure 1 and suggest that greater decreases in tumor blood flow, measured by CEUS early in therapy, may predict better outcome. The RSI for these patients did not predict time to progression and was not a valuable parameter. 
Tumor Response
Seventeen patients were evaluable for tumor response by RECIST. Figure 2 
rate was 29.4% (5/17) (95% CI, 12.4%-54.4%). Considering only confirmed PR, the observed response rate was 17.6% (3/17) (95% CI, 5.0%-41.7%).
DISCUSSION
In this study, the recommended dosage of the combination tested was found to be 90 mg/m 2 of sorafenib by mouth twice daily, 15 mg/kg of bevacizumab IV every 3 weeks, and 50 mg/m 2 of cyclophosphamide by mouth once daily. Although we were able to escalate the bevacizumab to its single-agent dose, we were unable to escalate the dose of sorafenib beyond approximately half of its single-agent dose due to HFS and elevated lipase. This finding is in contrast with the adult study of the combination sorafenib and bevacizumab in which neither drug was tolerable at the single-agent dose. The DLTs in adults included proteinuria and thrombocytopenia. (3) Overall, the study therapy was well tolerated and the toxicities manageable. Notable toxicities observed were dermatologic reactions and pneumothoraces. Skin reactions, primarily HFS attributed to sorafenib, have been reported to occur in 20% to 100% of patients. (19, 20) Thirteen of the 19 patients in our study had grade 1 or higher HFS. We learned as the study progressed that early initiation of emollients and initiation of pyridoxine therapy was beneficial and that interruption or dose reduction of sorafenib in most patients with grade 2 or 3 HFS prevented further progression or recurrence of skin toxicity.
Three patients in our study had a pneumothorax associated with tumor shrinkage and cavitation of pulmonary lesions. All three had a history of thoracotomies, but none had a history of spontaneous pneumothorax. Two of the patients were asymptomatic, and one patient died as a complication of pneumothorax following chest tube placement and pleurodesis. Spontaneous 
pneumothorax as a complication of anti-angiogenic therapy has been reported in the literature.(21-23) The mechanism is unknown but since the development of the pneumothorax seems to always be associated with necrosis and cavitation of the tumor lesion, we suspect that an air leak is generated as a consequence.
Objective responses and prolonged stabilization of disease in a variety tumor types were observed in our cohort of heavily pretreated patients, many of whom had rapidly progressive disease at study entry. The anti-tumor activity observed with the combination of sorafenib, bevacizumab, and low-dose cyclophosphamide appears to be greater than that observed with the reported activity of these drugs as single agents. Levels of angiogenic factors known to be targeted by the study therapy, VEGF, sVEGFR2, sVEGFR3, and PDGF, were variable through the first course of therapy and showed no correlation with response or disease stabilization in this small cohort of patients (data not shown). Interestingly, the only factor that showed a significant change from baseline to the end of the first course was sVEGFR3. VEGFR3 is expressed on the surface of lymphatic endothelial cells and is implicated in tumor lymphangiogenesis. We also detected a significant decrease in CEPs from baseline to end of course 1. Whether a change in plasma sVEGFR3 or CEPs could serve as a predictor for response, development of resistance or metastases, or outcome will require validation in a larger cohort of patients.
CEUS is emerging as reliable method to assess tumor vascularity in preclinical models and clinical trials. (42) (43) (44) (45) (46) We explored the use of CEUS as a noninvasive, less costly technique to assess tumor microcirculation in response to our anti-angiogenic therapy. We found that CEUS was well tolerated and easy to perform in children and adolescents. A limitation of this technique was that not all sites of disease were amenable to sonographic visualization. Nonetheless, although only 4 patients were fully evaluated by CEUS, it is noteworthy that the 2 patients who had a rapid decline in change of contrast flow through the tumor vasculature by day 7 had prolonged disease control in contrast to the 2 patients that did not have a rapid decline.
Furthermore, in the single patient who had serial CEUS and DCE-MRI performed, there was good correlation between the vascular flow measurements in the two modalities. These findings will require validation in a larger cohort of patients. If confirmed, then changes in tumor blood flow using CEUS could serve as an early surrogate imaging marker of response and as a useful tool in defining an optimal dose of anti-angiogenic therapy.
We have defined a recommended dose of sorafenib, bevacizumab, and low-dose cyclophosphamide for phase II testing. The combination is tolerable and shows promising antitumor activity in a variety of tumors; however, it should be used with caution in patients with pulmonary metastatic disease. This type of anti-angiogenic therapy would be ideal for maintenance therapy in the setting of minimal residual disease, although further investigation is needed to assess its degree of activity in various tumor types.
LEGEND Figure 1:
Change in signal intensity from pre-contrast baseline to initial post-contrast peak (∆SI, in decibels) through therapy in 4 patients who underwent contrast-enhanced ultrasound (CEUS) of target lesions. Patient 1 and 2 showed substantial decreases in ∆SI on days 3 and 7 and at the end of course 1, and both had long times to progression. The maximum decline in ∆SI in these two patients was 12.6 and 26.8 decibels, respectively. In contrast, patient 3 and 4 showing minimal decrease or an increase in ∆SI at the same early time points both had progressive disease by the end of course 1. The maximum decline in ∆SI in these two patients was 1.1 and 2.9 decibels, respectively. 
